Sam Heywood

464 total citations
18 papers, 318 citations indexed

About

Sam Heywood is a scholar working on Radiology, Nuclear Medicine and Imaging, Molecular Biology and Oncology. According to data from OpenAlex, Sam Heywood has authored 18 papers receiving a total of 318 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Radiology, Nuclear Medicine and Imaging, 9 papers in Molecular Biology and 5 papers in Oncology. Recurrent topics in Sam Heywood's work include Monoclonal and Polyclonal Antibodies Research (15 papers), Protein purification and stability (5 papers) and Glycosylation and Glycoproteins Research (4 papers). Sam Heywood is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (15 papers), Protein purification and stability (5 papers) and Glycosylation and Glycoproteins Research (4 papers). Sam Heywood collaborates with scholars based in United Kingdom, Belgium and United States. Sam Heywood's co-authors include David P. Humphreys, Shauna West, Alastair D. G. Lawson, Andrew D. Chalmers, Bruce Carrington, Joanne Compson, Paul Whitley, Ralph Adams, Katharine Cain and Pari Antoniw and has published in prestigious journals such as Journal of Biological Chemistry, PLoS ONE and Analytical Biochemistry.

In The Last Decade

Sam Heywood

17 papers receiving 306 citations

Peers

Countries citing papers authored by Sam Heywood

Since Specialization

Citations

This map shows the geographic impact of Sam Heywood's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sam Heywood with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sam Heywood more than expected).

Fields of papers citing papers by Sam Heywood

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sam Heywood. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sam Heywood. The network helps show where Sam Heywood may publish in the future.

Co-authorship network of co-authors of Sam Heywood

This figure shows the co-authorship network connecting the top 25 collaborators of Sam Heywood. A scholar is included among the top collaborators of Sam Heywood based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sam Heywood. Sam Heywood is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	POS0722 PURIFIED MONOCLONAL RHEUMATOID FACTORS BIND FC CONTAINING TNF INHIBITORS IN VITRO BUT NOT THE FC-FREE TNF INHIBITOR, CERTOLIZUMAB PEGOL 2024 ·Annals of the Rheumatic Diseases ·Sarah Bidgood, David Kallenberg, Anthony Turner, (unknown), (unknown), Katarzyna Mikula, (unknown), Hanna Hailu, (unknown), Stephen Cross, Kerry Tyson, Sam Heywood, (unknown), Bernard Lauwerys, (unknown), D. J. Humphreys, Anthony Shock	0
2	TRYBE®: an Fc-free antibody format with three monovalent targeting arms engineered for long in vivo half-life 2023 ·mAbs ·(unknown), (unknown), (unknown), Joanne Compson, (unknown), (unknown), Asher Maroof, (unknown), Karelle Ménochet, (unknown), (unknown), (unknown), (unknown), (unknown), Mark Ellis, (unknown), David P. Humphreys, Sam Heywood	3
3	The rational design of affinity-attenuated OmCI for the purification of complement C5 2018 ·Journal of Biological Chemistry ·(unknown), Xiaofeng Liu, (unknown), (unknown), Bruce Carrington, (unknown), Sam Heywood, Jean van den Elsen, Alastair D. G. Lawson	10
4	Cell surface dynamics and cellular distribution of endogenous FcRn 2017 ·PLoS ONE ·(unknown), Andrew D. Chalmers, Sam Heywood, Paul Whitley	34
5	PEGylation prolongs the pulmonary retention of an anti-IL-17A Fab’ antibody fragment after pulmonary delivery in three different species 2017 ·International Journal of Pharmaceutics ·(unknown), Harshad P. Patil, (unknown), Catherine Uyttenhove, Sam Heywood, Rita Vanbever	27
6	IgG light chain-independent secretion of heavy chain dimers: consequence for therapeutic antibody production and design 2017 ·Biochemical Journal ·(unknown), Paul E. Stephens, David P. Humphreys, Sam Heywood, Katharine Cain, Neil J. Bulleid	17
7	Extending the half-life of a fab fragment through generation of a humanized anti-human serum albumin Fv domain: An investigation into the correlation between affinity and serum half-life 2016 ·mAbs ·Ralph Adams, Laura Griffin, Joanne Compson, (unknown), Terry Baker, Tom Ceska, Shauna West, Oliver Zaccheo, (unknown), Alastair D. G. Lawson, David P. Humphreys, Sam Heywood	45
8	Production, purification and biological characterization of mono-PEGylated anti-IL-17A antibody fragments 2013 ·International Journal of Pharmaceutics ·(unknown), Sam Heywood, Catherine Uyttenhove, (unknown), Jacques Van Snick, Rita Vanbever	15
9	Towards a universal disulphide stabilised single chain Fv format: importance of interchain disulphide bond location and vL-vH orientation 2012 ·Protein Engineering Design and Selection ·(unknown), Katharine Cain, Sam Heywood, Joanne Compson, (unknown), Ralph Adams, David P. Humphreys	35
10	Detailing the Novel Structure of the Biopharmaceutical Certolizumab Pegol 2008 ·The American Journal of Gastroenterology ·Bryan John Smith, T.A. Ceska, (unknown), (unknown), Alison Turner, Sam Heywood, John O’Hara, Andrew Nesbitt	3
11	Investigation of the Distribution and Elimination of the PEG Component of Certolizumab Pegol in Rats 2008 ·The American Journal of Gastroenterology ·(unknown), Lloyd King, Judith van Asperen, Sam Heywood, Andrew Nesbitt	1
12	P150 DETAILING THE NOVEL STRUCTURE OF THE BIOPHARMACEUTICAL CERTOLIZUMAB PEGOL 2008 ·Bengt Smith, Tom Ceska, (unknown), (unknown), Anthony Turner, Sam Heywood, James E. O’Hara, Andrew Nesbitt	4
13	P068 INVESTIGATION OF THE DISTRIBUTION AND ELIMINATION OF THE PEG COMPONENT OF CERTOLIZUMAB PEGOL IN RATS 2008 ·(unknown), Lloyd King, Judith van Asperen, Sam Heywood, Andrew Nesbitt	6
14	Alternative antibody Fab′ fragment PEGylation strategies: combination of strong reducing agents, disruption of the interchain disulphide bond and disulphide engineering 2007 ·Protein Engineering Design and Selection ·David P. Humphreys, Sam Heywood, Alistair J. Henry, (unknown), Pari Antoniw, Roger Palframan, Kevin Greenslade, Bruce Carrington, (unknown), (unknown), Shauna West, (unknown)	37
15	Engineering of Escherichia coli to improve the purification of periplasmic Fab′ fragments: changing the pI of the chromosomally encoded PhoS/PstS protein 2004 ·Protein Expression and Purification ·David P. Humphreys, Sam Heywood, Lloyd King, (unknown), James P. Turner, (unknown)	9
16	Prolonged in Vivo Residence Times of Antibody Fragments Associated with Albumin 2001 ·Bioconjugate Chemistry ·Bryan John Smith, Andrew G. Popplewell, (unknown), Andrew P. Chapman, Sam Heywood, Shauna West, Bruce Carrington, Andrew Nesbitt, Alastair D. G. Lawson, Pari Antoniw, (unknown), Amanda Suitters	61
17	Development and Application of a Fluorometric Assay for Mammalian Membrane Dipeptidase 1995 ·Analytical Biochemistry ·Sam Heywood, Nigel M. Hooper	9
18	Inhibition of two gluconeogenic enzymes by glycosyl-phosphatidylinositol: a model for insulin action 1994 ·Biochemical Society Transactions ·Sam Heywood, Nigel M. Hooper	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact